Chronisch Lymphatische Leukämie (CLL)

INTERVENTIONELLE, MEDIKAMENTÖSE STUDIEN

Titel

A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVE) Compared to Obinutuzumab and Venetoclax (GVE) in Previously Untreated Patients With High Risk (17P-deletion, TP53-mutation or Complex Karyotype) Chronic Lymphatic Leukemia (CLL)

Indikation

Chronic Lymphatic Leukemia (CLL)

Art der Studie

Therapiestudie, Interventionell, Phase 3

Therapielinie

Erstlinientherapie

Hauptprüfer am Zentrum (PI)

Prof. Dr. med. C. Dierks

Ansprechpartner

J. Sen

Telefon: 0345/ 557 4853

Mail: ectu@uk-halle.de

Titel

A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6  cycles or 12 cycles of epcoritamab in patients with relapsed or refractory chronic  lymphocytic leukemia or small lymphocytic lymphoma

Indikation

Chronic Lymphatic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

Art der Studie

Therapiestudie, Interventionell, Phase 2

Therapielinie

ab Zweitlinientherapie

Hauptprüfer am Zentrum (PI)

Prof. Dr. med. C. Dierks

Ansprechpartner

J. Sen

Telefon: 0345/ 557 4853

Mail: juliane.sen@uk-halle.de

Titel

A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia

Indikation

Chronic Lymphatic Leukemia (CLL)

Art der Studie

Therapiestudie, Interventionell, Phase 2

Therapielinie

Zweitlinientherapie

Hauptprüfer am Zentrum (PI)

Prof. Dr. med. C. Dierks

Ansprechpartner

A. Kleinbauer

Telefon: 0345/ 557 1386

Mail: antje.kleinbauer@uk-halle.de

Titel

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Indikation

Chronic Lymphatic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

Art der Studie

Therapiestudie, Interventionell, Phase 3

Therapielinie

Erstlinientherapie

Hauptprüfer am Zentrum (PI)

Prof. Dr. med. C. Dierks

Ansprechpartner

J. Sen

Telefon: 0345/ 557 4853

Mail: juliane.sen@uk-halle.de